Literature DB >> 8998385

Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine.

J E Ridings1, A K Palmer, E J Davidson, J A Baldwin.   

Abstract

In prenatal toxicity studies, diproteverine, a calcium channel blocker with demonstrated antianginal properties, produced an unusual pattern of digital, heart, tail, and vertebral defects in rat fetuses from mothers treated during the major period of organogenesis, but only a very low incidence of heart abnormalities was seen in the rabbit. Heart changes were rarely seen in association with digital defects. The findings were consistent with those seen with other calcium channel blockers and add weight to the suggestion of Danielsson and colleagues (5) that digital malformations are a class effect for this type of compound, the effects being related to reduced uteroplacental blood flow. In addition, it is proposed that cardiovascular malformations are also a class response with calcium channel blockers. The distribution of fetal death and hemorrhages and the varying association between cardiovascular, digital, and tail abnormalities seen in the rat with increasing doses of diproteverine fits the pattern of changes reported following hypoxia in the chick embryo. Reduced uteroplacental blood flow with resultant embryonic hypoxia secondary to pharmacologic action is considered a probable mechanism of action for the induction of abnormalities produced by calcium channel blockers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8998385     DOI: 10.1016/0890-6238(95)02017-9

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  1 in total

1.  Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations.

Authors:  Alissa R Caton; Erin M Bell; Charlotte M Druschel; Martha M Werler; Angela E Lin; Marilyn L Browne; Louise-Anne McNutt; Paul A Romitti; Allen A Mitchell; Richard S Olney; Adolfo Correa
Journal:  Hypertension       Date:  2009-05-11       Impact factor: 10.190

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.